| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.17 | 0.008 |
| mRNA | GW843682X | CTRPv2 | pan-cancer | AAC | 0.099 | 0.008 |
| mRNA | Erlotinib | FIMM | pan-cancer | AAC | 0.43 | 0.008 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | 0.094 | 0.009 |
| mRNA | vorinostat:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.1 | 0.009 |
| mRNA | NG-25 | GDSC1000 | pan-cancer | AAC | 0.088 | 0.009 |
| mRNA | I-BET151 | CTRPv2 | pan-cancer | AAC | 0.088 | 0.009 |
| mRNA | PHA-793887 | CTRPv2 | pan-cancer | AAC | 0.089 | 0.009 |
| mRNA | BRD-K27986637 | CTRPv2 | pan-cancer | AAC | -0.22 | 0.009 |
| mRNA | BRD-K51490254 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.009 |